Humoral Immunity after mRNA Omicron JN.1 Vaccination
Happle, C.; Hoffmann, M.; Kempf, A.; Nehlmeier, I.; Stankov, M. V.; Calderon Hampel, N.; Witte, T.; Poehlmann, S.; Behrens, G. M.; Dopfer-Jablonka, A.
Show abstract
In late June 2024, the European Medicines Agency (EMA) recommended market authorization for a monovalent COVID-19 mRNA-vaccine based on JN.1 spike. We assessed immune responses in n=42 health-care workers (median age 47 years, interquartile range, IQR 19{middle dot}5 years, 48% male), who in August 2024 were vaccinated with 30 g of the updated mRNA omicron JN.1 vaccine (bretovameran, BioNTech/Pfizer, Mainz, Germany). Humoral immune responses were analyzed directly prior to and 13 days after vaccination. The omicron JN.1 vaccination resulted in a significant 1{middle dot}2-fold increase of anti-S IgG and 1{middle dot}2-fold increase of omicron anti-S IgG (p<0{middle dot}0001). To assess plasma neutralisation capacity, we employed a pseudovirus particle (pp) neutralisation assay including S proteins of seven SARS-CoV-2 lineages. Baseline response rates were 100% for XBB.1.5pp, 90% for JN.1pp and KP.2pp, 82% for KP.2.3pp, 92% for KP.3pp, and 72% for LB.1pp. Before JN.1 vaccination, particles bearing KP sublineage S proteins were slightly less efficiently neutralised compared with JN.1pp (median change, 1{middle dot}2-fold to 2{middle dot}6-fold), while LB.1pp neutralisation was 3-fold reduced, indicating antibody evasion. After vaccination, the response rates increased significantly for all pseudoviruses except XBB.1.5pp and KP.3pp. Thus, we observed a significant increase in neutralisation of JN.1pp, KP.2pp, KP.2.3pp, and LB.1pp, showing a median change of 2.2-fold, 3.8-fold, 3.3-fold, and 4.9-fold, respectively. In summary, bretovameran increased anti-S IgG and strengthened neutralising responses against circulating SARS-CoV-2-variants, except for KP.3. We wish to point out that our study population exhibited high pre-vaccination omicron-related hybrid immunity and may not be representative of other populations. Our data supports the notion that the new mRNA vaccine against omicron JN.1 most likely increases protection against hospitalization and post-COVID sequelae caused by most current variants.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Predicting the efficacy of variant-modified COVID-19 vaccine boosters 94%
- Immunogenicity and reactogenicity of a heterologous COVID-19 prime-boost vaccination compared with homologous vaccine regimens 94%
- mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant 94%
Similar papers in this journal
- Effect of booster vaccination against Delta and Omicron variants in Iceland 96%
- Safety, tolerability, and immunogenicity of a new SARS-CoV-2 recombinant Gamma variant RBD-based protein adjuvanted vaccine, used as heterologous booster in healthy adults: a Phase 1 interim report 96%
- Distinct COVID-19 vaccine combinations result in divergent immune responses 95%
Similar papers in this journal
- Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report 95%
- A Phase 1: Safety and Immunogenicity Trial of an Inactivated SARS-CoV-2 Vaccine-BBV152 94%
- Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: a randomised, placebo-controlled, dose-ranging study 94%
Similar papers in this journal
- Immunogenicity of a third dose of BNT162b2 to ancestral SARS-CoV-2 & Omicron variant in adults who received two doses of inactivated vaccine 95%
- Humoral and cellular immune responses against SARS-CoV-2 variants and human coronaviruses after single BNT162b2 vaccination 94%
- Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the Delta variant epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS) 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.